| Intraviteal Bevacizumab (Avastin(R)) Injection for the Treatment of Early-Stage Neovascular Glaucoma. |
|
Hyosung Maeng, Jinchul Kim, Changwon Kee |
|
Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. cwkee@skku.edu |
| 초기 신생혈관 녹내장에서 Bevacizumab (Avastin®)를 이용한 치료 1예 |
|
맹효성ㆍ김진철ㆍ기창원 |
|
Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea |
|
|
| Abstract |
PURPOSE
This case is conducted to assess the short term safety and efficacy of intravitreal bevacizumab injection in patient with early stage of the neovascular glaucoma (NVG) without peripheral anterior synechiae. CASE SUMMARY: A 66 year old patient with a history of proliferative diabetic retinopathy presented with neovascularization of the iris and the angle and high intraocular pressure of 30 mmHg. The patient received a single injection of bevacizumab (1.25 mg /0.05 mg) intravitreally. The visual acuity (VA), intraocular pressure (IOP), regression of the iris and the angle neovascularization were measured up to the twenty ninth week after injection. Regression of the iris and angle neovascularization were confirmed from the second week after injection. The visual acuity had continued stable and the IOP had been controlled from 30 mmHg to 20 mmHg from fifth week without the need for topical antiglaucoma medications until the twenty ninth week. CONCLUSIONS: Bevacizumab may be an effective medication for the treatment of neovascular glaucoma. Bevacizumab seems to be a useful adjunct or an advantageous treatment option to panretinal photocoagulation in the treatment of neovascular glaucoma. |
| Key Words:
Intravitreal bevacizumab injection;Early-stage neovascular glaucoma;Panretinal photocoagulation |
PDF Links
Full text via DOI
Download Citation
